All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | Antibody Clone | Host | Hinge | TM | ICD | Inquiry & Datasheet |
CARMA-W0091 | Anti-CD21 (THB-5) ICD(CD147) CAR-MA Plasmid, pCDCAR1 | Human | THB-5 | Mouse | IgG1 | CD147 | CD147 | |
CARMA-W0092 | Anti-CD21 (THB-5) ICD(CD86+FcγRI) CAR-MA Plasmid, pCDCAR1 | Human | THB-5 | Mouse | CD8 | CD8 | CD86+FcγRI | |
CARMA-W0093 | Anti-CD21 (THB-5) ICD(CD3ζ) CAR-MA Plasmid, pCDCAR1 | Human | THB-5 | Mouse | CD8 | CD8 | CD3ζ | |
CARMA-W0094 | Anti-CD21 (THB-5) ICD(Megf10) CAR-MA Plasmid, pCDCAR1 | Human | THB-5 | Mouse | CD8 | CD8 | Megf10 | |
CARMA-W0095 | Anti-CD21 (THB-5) ICD(FcRɣ) CAR-MA Plasmid, pCDCAR1 | Human | THB-5 | Mouse | CD8 | CD8 | FcRɣ | |
CARMA-W0096 | Anti-CD21 (THB-5) ICD(FcRɣ+PI3K) CAR-MA Plasmid, pCDCAR1 | Human | THB-5 | Mouse | CD8 | CD8 | FcRɣ+PI3K | |
CARMA-W0097 | Anti-CD21 (HB135) ICD(CD147) CAR-MA Plasmid, pCDCAR1 | Human | HB135 | Human | IgG1 | CD147 | CD147 | |
CARMA-W0098 | Anti-CD21 (HB135) ICD(CD86+FcγRI) CAR-MA Plasmid, pCDCAR1 | Human | HB135 | Human | CD8 | CD8 | CD86+FcγRI | |
CARMA-W0099 | Anti-CD21 (HB135) ICD(CD3ζ) CAR-MA Plasmid, pCDCAR1 | Human | HB135 | Human | CD8 | CD8 | CD3ζ | |
CARMA-W0100 | Anti-CD21 (HB135) ICD(Megf10) CAR-MA Plasmid, pCDCAR1 | Human | HB135 | Human | CD8 | CD8 | Megf10 | |
CARMA-W0101 | Anti-CD21 (HB135) ICD(FcRɣ) CAR-MA Plasmid, pCDCAR1 | Human | HB135 | Human | CD8 | CD8 | FcRɣ | |
CARMA-W0102 | Anti-CD21 (HB135) ICD(FcRɣ+PI3K) CAR-MA Plasmid, pCDCAR1 | Human | HB135 | Human | CD8 | CD8 | FcRɣ+PI3K |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION